Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy
Hai-Xing Mai1, Guo-Hui Mei1, Fei-Long Zhao2, Bo-Tao Li3, Yong-Yong Tang3, Bin Zhang3, Xiao-Jie Xu4, Li-Jun Chen5
1 Department of Urology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China
2 Department of Urology, Clinical College, No. 307 Hospital of PLA, Anhui Medical University, Beijing 100071, China
3 Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital of Academy of Military Medical Sciences; Cell and Gene Therapy, Academy of Military Medical Sciences, Beijing 100071, China
4 Department of Medical Molecular Biology, Beijing Institute of Biotechnology, 27 Tai-Ping Lu Rd, Beijing 100850, China
5 Department of Urology, Affiliated Hospital of Academy of Military Medical Sciences; Department of Urology, Clinical College, No. 307 Hospital of PLA, Anhui Medical University, Beijing 100071, China
Department of Urology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071
Source of Support: None, Conflict of Interest: None
Objective: Sunitinib/sorafenib (SU/SO), dendritic cells (DCs), or DC-cytokine-induced killer (CIK) could significantly prolong progression-free survival (PFS), 3-year overall survival (OS), or 5-year OS for patients with metastatic renal cell carcinoma (mRCC). We retrospectively analyzed the clinical efficacy between SU/SO combined with DC-CIK and SU/SO monotherapy in treating renal cell carcinoma (RCC) patients with metastasis after radical nephrectomy.
Materials and Methods: All patients (n = 34) with postoperative mRCC in our hospital from January 2009 to January 2014 were received either SU/SO monotherapy (Group 1, n = 15) or in combination with DC-CIK (Group 2, n = 19). A retrospective study was based on the primary endpoint (PFS) and secondary endpoint (OS).
Results: At a median follow-up of 19.5 months, in Group 2, as compared with in Group 1, the median PFS was significantly longer (28.0 vs. 11.0 months, P = 0.03). Moreover, the 3-year OS was higher (57.1% vs. 28.6%). The cases of progressive diseases (PDs) and deaths were less in Group 2 than that in Group 1 (PD: 8 vs. 9, deaths: 3 vs. 5); however, the cases of stable diseases were more (11 vs. 6). In addition, the 3-year OS was higher in SU + DC-CIK group than that in SO + DC-CIK group (63.36% vs. 50%). There was no significant difference for PFS between SO + DC-CIK group and SU single agent group.
Conclusions: SU/SO with DC-CIK could significantly prolong the median PFS, improve the 3-year OS rate, prolong the 3-year OS. It is likely to be a new approach for mRCC after radical nephrectomy.